Source link : https://www.newshealth.biz/health-news/jak-inhibitor-succeeds-in-giant-cell-arteritis-trial/
WASHINGTON — Giant cell arteritis (GCA) can be successfully treated with the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq), allowing corticosteroids to be withdrawn, results of a phase III trial indicated. Among 209 GCA patients receiving the drug at 15 mg/day, 46.4% achieved clinical remission without needing rescue steroids during weeks 12-52 in the study, […]
Author : News Health
Publish date : 2024-11-16 22:17:19
Copyright for syndicated content belongs to the linked Source.
inHealth